Drugplain

GRAFAPEX 1000 mg/g

treosulfan · INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION · Medexus Pharma, Inc.

No Recall History
Plain English

Grafapex (treosulfan) is an intravenous chemotherapy medication used to prepare the body for bone marrow or stem cell transplantation. It works by destroying cancer cells and bone marrow cells to make room for transplanted healthy cells.

Key Facts

Brand Name
GRAFAPEX
Generic Name
treosulfan
NDC Code (Product)
59137-335
Manufacturer
Medexus Pharma, Inc.
Strength
1000 mg/g
Dosage Form
INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION
Route
INTRAVENOUS
Marketing Status
Application #
NDA214759
Marketing Start
01/28/2025

Recall History

No Recall History

Side Effects Reported to FDA

FDA FAERS database · These are reported events, not confirmed side effects

off label use596 reports
cytomegalovirus infection259 reports
cytomegalovirus infection reactivation246 reports
mucosal inflammation233 reports
drug ineffective227 reports
product use in unapproved indication225 reports
adenovirus infection204 reports
acute graft versus host disease in skin198 reports
graft versus host disease in skin145 reports
acute graft versus host disease126 reports

Frequently Asked Questions

What is GRAFAPEX used for?

Grafapex (treosulfan) is an intravenous chemotherapy medication used to prepare the body for bone marrow or stem cell transplantation. It works by destroying cancer cells and bone marrow cells to make room for transplanted healthy cells.

Is GRAFAPEX a controlled substance?

GRAFAPEX is not classified as a controlled substance by the DEA.

What is the generic name for GRAFAPEX?

The generic name for GRAFAPEX is treosulfan. There are no other listed brand versions of treosulfan.

What is the NDC code for GRAFAPEX 1000 mg/g?

The NDC (National Drug Code) for GRAFAPEX 1000 mg/g is 59137-335, listed by Medexus Pharma, Inc..

Product NDC

59137-335

Package NDC

59137-335-01

Other GRAFAPEX Dosages

Not medical advice. Always consult your doctor or pharmacist before making any medication decisions.

Data from openFDA · Public domain (CC0 1.0)